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Abstract
Background: Somatostatin prevents cell proliferation by inducing apoptosis. Downregulation of the XAF1 transcript
may occur during the development of prostate cancer. It is interesting to evaluate the potential regulatory effects
of somatostatin on XAF1 expression during the development of prostate cancer cells.
Methods: XAF1 mRNA and protein expression in human prostate epithelial cells RWPE-1, androgen dependent
prostate cancer LNCaP, and androgen independent DU145 and PC3 cells were evaluated using RT-PCR and
Western blot. The regulation of XAF1 mRNA and protein expression by somatostatin and its analogue Octreotide
was evaluated.
Results: Substantial levels of XAF1 mRNA and proteins were detected in RWPE-1 cells, whereas prostate cancer
cells LNCaP, DU145 and PC3 exhibited lower XAF1 expression. Somatostatin and Octreotide up-regulated XAF1
mRNA and protein expression in all prostate cancer cell lines.
Conclusions: XAF1 down-regulation may contribute to the prostate cancer development. The enhanced XAF1
expression by somatostatin indicates a promising strategy for prostate cancer therapy.
Background
Prostate cancer is the most common cancer and the
leading cause of cancer death among men in the United
States and Europe [1,2]. It was estimated that approxi-
mately 186,320 new cases and 28,660 prostate cancer-
related deaths occurred in the US in 2008 [1]. Although
epidemiological studies showed that the incidence of
prostate cancer in Asians is much lower than that in
African-Americans [3], the occurrence of the disease has
rapidly increasing in China[4]. Most prostate cancers are
initially androgen-dependent but become androgen-
independent and refractory to hormone withdrawal
therapy [5]. Like all other human malignancies, prostate
cancer cells escape apoptotic death through highly effi-
cient pathways involving multiple mechanisms [6,7].
X-linked inhibitor of apoptosis protein-associated fac-
tor-1 (XAF1)w a sf i r s ti d e n t i f i e da sa ni n t e r a c t i n gp r o -
tein of X-linked inhibitor of apoptosis (XIAP) [8]. XIAP
suppresses apoptotic cell death by binding to caspases
and inhibiting their functions. XAF1 antagonizes XIAP
activities, thereby promoting apoptosis [9]. XAF1 can
dramatically sensitize cancer cells to apoptotic triggers
such as TRAIL, etoposide treatments 5-fluorouracil [10],
H2O2, c-irradiation, ultraviolet [11], and tumour necro-
sis factor-a, which are independent of its interaction
with XIAP [12]. XAF1 is therefore believed to play an
important role in the major apoptosis-related pathways.
XAF1 also serves as a candidate tumour suppressor
gene. Loss of XAF1 has been observed in a variety of
cancer cell lines and human cancers [13-16]. However,
little is yet known about its potential implication in
prostate cancer.
So far, there have been no effective therapeutic mea-
sures for the treatment of hormone refractory prostate
cancer. Treatment with somatostatin may therefore be a
possible therapeutic alternative to chemotherapy in hor-
mone refractory prostate cancer patients. Somatostatin,
originally identified as a neuropeptide inhibiting growth
hormone release more than 30 years ago, is widely pre-
sent in central and peripheral human cells/tissues
including prostate. Somatostatin has been shown to
exert a potent anti-tumour action by affecting tumour
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any medium, provided the original work is properly cited.cell proliferation, apoptosis, angiogenesis and the host’s
immune response [17-21]. Octreotide is an analogue of
somatostatin and has been used in clinical practice since
data emerged in the 1980 s confirming its ability to pal-
liate carcinoid syndrome [22]. Our previous results have
shown that somatostatin may affect the mitochondria of
LNCaP and DU145 cells in a way that eventually trig-
gers mitochondrial-mediated apoptosis and exert its
effects on prostate cancer cells via MAPK pathway and
by regulating the activities of phosphotyrosine phospha-
tases [23].
In the current study, we examined XAF1 mRNA and
protein expression in four cell lines, and determined
regulatory effects of somatostatin and Octreotide on
XAF1 expression in prostate cancer cell lines. We found
that somatostatin and Octreotide up-regulated XAF1
mRNA and protein expression in prostate cancer cell
lines. The enhanced XAF1 expression by somatostatin
indicates a promising strategy for prostate cancer
therapy.
Materials and methods
Cell lines and cell culture
A human prostate epithelial cell line (RWPE-1) and
prostate cancer cell lines (LNCaP, DU145 and PC3)
were used and were obtained from the American Type
Culture Collection (ATCC). LNCaP, DU145 and PC3
were maintained in RPMI-1640 medium supplemented
with 10% foetal bovine serum (FBS). RWPE-1 cells were
maintained in complete keratinocyte serum-free medium
(K-SFM) containing 50 μg/ml bovine pituitary extract
and 5 ng/ml epidermal growth factor. The cultures were
maintained in a humidified 5% CO2 e n v i r o n m e n ta t3 7 °
C. The medium was changed twice a week and the cells
were trypsinized and subcultivated once a week. Soma-
tostatin and Octreotide (Sigma) were prepared as
described previously [24]. The cells were treated with 1
nM somatostatin and 1 nM Octreotide for different per-
iods of time (0, 1 h, 12 h, 24 h, 72 h), as described by
Brevini [25]. Controls were untreated cells.
RNA extraction and RT-PCR
XAF1 mRNA was detected using reverse transcription
PCR (RT-PCR). Total cellular RNA was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA), according to
the manufactures’ instruction. cDNA was synthesized
using random primers (N6) and M-MLV reverse tran-
scriptase. PCR was performed by using XAF1-specific
p r i m e r sa sf o l l o w s :f o r w a r d :5 ’-ATG GAA GGA GAC
TTC TCG GT-3’;r e v e r s e :5 ’-TTG CTG AGC TGC
ATG TCC AG-3’ and the conditions were: denaturation
at 94°C for 5 min, followed by 34 cycles of 94°C 30 s,
60°C 30 s, 72°C 45 s, and then a final cycle of 10 min at
72°C. Amplification products (290 bps) were
electrophoresed onto 1.5% agarose gels and visualized
by 0.5% ethidium bromide staining. The results of elec-
trophoresis were analyzed by the Gel Image System
Fluor Chem TM 9900 (Alpha Innotech).
Western blot analysis
Cells were lysed in buffer containing 50 mM Tris-HCl
(pH 7.5), 250 mM NaCl, 0.1% NP-40 and 5 mM EGTA,
50 mM sodium flu-oride, 60 mM b-glycerol-phosphate,
0.5 mM sodium-vanadate, 0.1 mM PMSF, 10 μg/ml
aprotinin and 10 μg/ml leupeptin. Protein concentration
was determined using the BCA protein assay kit (Pierce
Bio-technology, Inc., USA). Protein samples (40 μg)
were subjected to a 10% SDS-PAGE and electrophoreti-
cally transferred to PVDF membranes (Bio-Rad,
H e r c u l e s ,C A ,U S A ) .T h em e m b r a n e sw e r ef i r s ti n c u -
bated with 5% nonfat milk in Tris-buffered saline (TBS).
After washing three times in 0.1% Tween 20-TBS
(TBST), the membranes were incubated with primary
antibody (goat anti-human XAF1, 1:600; Santa Cruz Bio-
tecnology) and b-actin (rabbit anti-actin antibody R-22,
1:1000; Santa Cruz Biotecnology) separately at 4°C over-
night, followed with the corresponding secondary anti-
bodies separately (1:2500) for 1.5 h at room temperature
and the antibody-bound proteins were detected by the
ECL system (Amersham Biosciences, Little Chalfont
Buckinghamshire, UK).
Results
Expression of XAF1 mRNA and protein in prostate cell
lines
The expression of XAF1 was detected at mRNA and
protein levels with RT-PCR and Western blot. As
shown in Figure 1, RT-PCR using cDNA primers speci-
fic for a segment of the human XAF1 mRNA provided a
product of the expected size in four prostate cell lines.
It showed lower expression of XAF1 mRNA in prostate
cancer cells LNCaP, DU145 and PC3 compared with
that in RWPE-1 cells which displayed the strongest
expression of XAF1 mRNA among all four cell lines.
We found protein expression of XAF1 in these same cell
lines by Western blot analysis, consistent with XAF1
mRNA expression. (Figure 1).
Up-regulation of XAF1 mRNA and protein by somatostatin
and Octreotide in prostate cancer cell lines
To examine the regulatory effects of somatostatin and
Octreotide on XAF1 mRNA and protein expression,
prostate cancer cell lines (LNCaP, DU145 and PC3)
were stimulated with 1 nM somatostatin and 1 nM
Octreotide for different periods of time. We found a
time-dependent manner of up-regulation of XAF1
mRNA and protein in the cells treated with somatosta-
tin and Octreotide (Figure 2, 3 and 4).
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Most prostate tumours are initially androgen-dependent
but become androgen-independent and eventually
refractory to the hormone [5]. There are many regula-
tive factors among its progression, relapse and tumour
outgrowth. Prostate cancer cells evade apoptotic cell
death by a variety of mechanisms [6,7]. XAF1,ap o t e n t
apoptosis-inducer [8], plays a significant role in the pro-
cess. A number of studies have shown that XAF1 can
sensitize cancer cells to TRAIL, TNF-a,F a s ,I F N - b and
MEK inhibitor-induced apoptosis in vitro [12,26-29].
Moreover, some researchers have recently indicated the
effect of XAF1 combination with these factors on inhibi-
tion of tumour growth in vivo and demonstrated that
XAF1 can hinder tumour progression and promote out-
right regression in combination with TRAIL [30]. XAF1
mRNA is expressed at low or undetectable levels in
most cancer cell lines, and transcriptional down-regula-
tion in tumour cells as opposed to corresponding nor-
mal tissues and has been shown to occur at different
frequencies in gastric adenocarcinomas, colorectal can-
cer, urothelial carcinomas, malignant melanomas, clear-
cell renal cell carcinomas [8,13-16,31], non-small cell
lung cancer, bladder cancer and B chronic lymphocytic
leukemia [15,32,33].
Human prostate epithelial cells (RWPE-1) and pros-
tate cancer cells (LNCaP, DU145 and PC3), which exhi-
bit different features of prostate cancer progression
from early stages to androgen independent stages, could
mimic the development of prostate cancer clinically.
Understanding the regulating effects of XAF1 during the
whole progression may help us find potential therapeu-
tic strategies for prostate cancer patients. To our knowl-
edge, little is yet known about the regulatory effects of
XAF1 in many different types of human cancers. Three
prostate cancer cell lines LNCaP, DU145 and PC3 were
well established in laboratory experiments. Their inva-
sive characteristics were found to be different among
the three cell lines: lower invasive ability of LNCaP,
medium invasive ability for DU145 and a higher ability
for PC3. The varying expression of XAF1 suggests a
causal changing of androgen dependency and invasive-
ness in the development of prostate cancer.
The antiproliferative effect of somatostatin may result
from increased apoptosis. In breast cancer cells MCF-7,
the cytotoxic effect of somatostatin is dependent on
SHP-1 and results from caspase 8 activation, cell acidifi-
cation and mitochondrial dysfunction [34]. Apoptosis is
induced by SSTR3 as a result of the induction of p53
and Bax [35] and is also induced by SSTR2 in HL-60
Figure 1 Expression of XAF1 mRNA and protein in human prostate cell lines.a .R T - P C Ra n a l y s i so fXAF1 mRNA; the b-actin transcript was
analyzed as a control. b. Western blot analysis of XAF1 protein; the b-actin was as a control.
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Page 3 of 8Figure 2 Time-dependent somatostatin and Octreotide-induced expression of XAF1 mRNA and protein in LNCaP cell line. Cells were
stimulated with 1 nM somatostatin (a and b) and 1 nM Octreotide (c and d) for the time periods indicated. a and c: RT-PCR results. b and d:
Western blot. Oct: Octreotide; sms: somatostatin.
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Page 4 of 8Figure 3 Time-dependent somatostatin and Octreotide-induced expression of XAF1 mRNA and protein in DU145 cell line. Cells were
stimulated with 1 nM somatostatin (a and b) and 1 nM Octreotide (c and d) for the time periods indicated. a and c: RT-PCR results. b and d:
Western blot. Oct: Octreotide; sms: somatostatin.
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Page 5 of 8Figure 4 Time-dependent somatostatin and Octreotide-induced expression of XAF1 mRNA and protein in PC3 cell line. Cells were
stimulated with 1 nM somatostatin (a and b) and 1 nM Octreotide (c and d) for the time periods indicated. a and c: RT-PCR results. b and d:
Western blot. Oct: Octreotide; sms: somatostatin.
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human pancreatic cancer cells expressing mutated p53
and devoid of endogenous SSTR2, after correction of
the deficiency by expression of SSTR2 [37]. Thus,
somatostatin can induce apoptosis by p53-dependent
and -independent mechanisms. SSTR2 induces apo-
ptosis in a tyrosine phosphatase SHP-1-dependent
manner.
Currently, several somatostatin analogues including
Octreotide, Lanreotide, Vapreotide, Seglitide and so on,
are available for the treatment of several kinds of disor-
ders. Octreotide was the first developed analogue and is
widely used for symptomatic treatment of hormone
secreting neuroendocrine tumours. It has higher affinity
for SSTR2 and shows significant anti-neoplastic actions
in tumours expressing SSTR2 [38]. It remains the drug
of choice for application in a majority of pure NE
tumours because such tumours predominantly express
SSTR2 [39]. However, other somatostatin analogues
such as Lanreotide, which have good affinity for SSTR5
in addition to that for SSTR2, may advantageously
recognize SSTR5 expressing tumours. But the relation-
ship between XAF1 and somatostatin receptors needs
further elucidation.
In our previous studies [24], we found that somatosta-
tin up-regulated the expression of SSTR1-5, and that
apoptosis was activated mainly via the induced expres-
sions of SSTR2 and SSTR3. The effects of somatostatin
on the prostate cancer cells may be mediated by
enhanced expression of XAF1 through its pro-apoptotic
effect. Somatostatin and Octreotide up-regulate XAF1
mRNA and protein in all prostate cancer cell lines, but
the underlying mechanisms need further investigations.
Likely, up-regulation of XAF1 mediated by somatostatin
and Octreotide triggers cancer cell apoptosis.
Conclusions
To our knowledge, little is known about the regulatory
effects of XAF1 in many different types of human can-
cers. We report, the first time, that somatostatin and
Octreotide up-regulate XAF1 mRNA and protein
expression in LNCaP, DU145 and PC3 prostate cancer
cell lines. Our findings suggest that XAF1 down-regula-
tion may contribute to the prostate cancer develop-
ment. The enhanced XAF1 expression by somatostatin
indicates a promising strategy for prostate cancer
therapy.
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